The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.
 
Ta-Chen Huang
No Relationships to Disclose
 
Chia-Chi Lin
No Relationships to Disclose
 
Kai-Yuan Tzen
No Relationships to Disclose
 
Yun-Chun Wu
No Relationships to Disclose
 
Jason Chia-Hsien Cheng
No Relationships to Disclose
 
Jang-Ming Lee
No Relationships to Disclose
 
Hsiu-Po Wang
No Relationships to Disclose
 
Pei-Ming Huang
No Relationships to Disclose
 
Feng-Ming Hsu
No Relationships to Disclose
 
Kun-Huei Yeh
No Relationships to Disclose
 
Ann-Lii Cheng
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Merck Serono; Novartis; ONXEO
Speakers' Bureau - Novartis
Research Funding - Sanofi
 
Chih-Hung Hsu
Honoraria - Bayer; Bristol-Myers Squibb
Consulting or Advisory Role - Lilly; MSD; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca; MSD; Ono Pharmaceutical